Glucagon News and Research

RSS

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

Same foods, different timing, very different glucose patterns

In a randomized crossover study of 22 healthy, normal-weight Chinese men, consuming canola oil alone or with spinach before a high-glycemic mashed-potato meal produced flatter post-meal glucose and insulin responses than spinach alone or no preload. The effects were associated with increased GLP-1 signaling and slower gastric emptying, with the findings indicating that the unsaturated oil was the primary driver of the metabolic response.

3 Sep 2026

Study links popular weight-loss drugs to increased male hair loss

Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

3 Sep 2026

Why addiction researchers are paying closer attention to GLP-1 drugs

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions.

2 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Ketogenic diet provides greatest health benefits for treating obesity

A diet that severely limits carbohydrates but is high in fat has the greatest health benefits for people with obesity compared to a Mediterranean diet or a low-fat diet, according to a clinical trial publishing August 27 in the Cell Press journal Cell Metabolism.

27 Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

26 Aug 2026

Consistent meal logging drives major weight loss in app users

The people who log their meals most days of the week lose the most weight. This is the central finding of a peer-reviewed study of 5132 MyNetDiary users, published on August 13, 2026, in the Journal of Medical Internet Research.

25 Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

24 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

What happens to body fat when people follow the Eatwell Guide?

Higher adherence to the UK Eatwell Guide was associated with lower BMI, waist circumference, total body fat, and trunk fat in more than 156,000 UK Biobank participants. The associations persisted prospectively across demographic, physical activity, and genetic-risk groups, supporting the role of diet quality in weight management.

16 Aug 2026

Sprint exercise sends a very different molecular signal through the body

Sprint-interval exercise triggers a much larger and faster shift in circulating proteins and metabolites than moderate-intensity exercise, revealing distinct patterns of predicted communication between organs. The findings suggest that exercise intensity shapes systemic molecular signaling, with skeletal muscle and adipose tissue emerging as potential source and target tissues linked to cardiometabolic health.

16 Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

10 Aug 2026

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

In a US cohort of 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide initiation was associated with a lower one-year risk of major adverse cardiovascular events than sitagliptin. The benefit was driven mainly by lower myocardial infarction and all-cause mortality hazards, although the authors cautioned that mortality findings may be influenced by residual confounding.

10 Aug 2026

New review highlights FOXA2's role in glucose regulation pathways

A newly published review highlights the pivotal role of FOXA2, a key transcription factor, in coordinating pancreatic development, maintaining islet cell identity, and regulating glucose homeostasis.

6 Aug 2026

Mouse study shows how liraglutide briefly rewires gut bacterial communities

Researchers treated male high-fat-fed mice with liraglutide for 14 days, then tracked fecal bacterial communities after a 7-day washout using 16S rRNA sequencing. Liraglutide shifted the microbiome toward Lactobacillus- and Leptogranulimonas-related taxa while reducing several fermentative taxa, but most changes moved back toward baseline after treatment stopped.

4 Aug 2026